

Review of: "[Research Note] Semaglutide, a GLP-1 Agonist Like Ozempic, and Its Potential Role as a Preventive Anti-Cancer Agent"

Zaid Younus¹

¹ University of Mosul

Potential competing interests: No potential competing interests to declare.

The overall subject is nice and highlights an interesting aspect of GLP-1 receptor agonists. Still, you need to address the following points before publication:

- 1- Semaglutide is the same as Ozempic; you don't need to mention both here. Also, it's better not to use acronyms or abbreviations in the title. I suggest rephrasing the title; for instance, "Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, and Its Potential Role as a Preventive Anti-Cancer Agent."
- 2- In the abstract, write the full GLP-1 name, then abbreviate it in brackets, and after that, use the abbreviated name throughout.
- 3- Language revisions are required all over the text. It's difficult to follow what has been written, and many times it's misleading. I recommend using more simplified phrases and expressions.
- 4- On page 2, the following sentence "... numerous studies have sought to unravel the optimal dosage of GLP-1 for..." needs to cite 2 or 3 studies and to discuss some aspects of these studies in more detail—what they have done and what their conclusions are. It also needs an enhanced discussion of the mechanism of GLP-1 in cancer protection by citing more studies and referring to their outcomes.
- 5- More evidence needs to be discussed about the dosage. Also, why discuss Exenatide when your work is targeting Semaglutide? This needs to be addressed.